Literature DB >> 12135949

Synthesis of collagen is dysregulated in cultured fibroblasts derived from skin of subjects with varicose veins as it is in venous smooth muscle cells.

Patricia Sansilvestri-Morel1, Alain Rupin, Stéphane Jaisson, Jean-Noël Fabiani, Tony J Verbeuren, Paul M Vanhoutte.   

Abstract

BACKGROUND: The dilatation and tortuosity observed in varicose veins provide evidence for progressive venous wall remodeling associated with abnormalities of smooth muscle cells and extracellular matrix. The present study was designed to examine if the phenotypic modulations observed in the venous smooth muscle cells of patients with varicose veins were also present in their dermal fibroblasts. METHODS AND
RESULTS: Collagen type I (collagen I), type III (collagen III), and type V (collagen V) were compared in dermal fibroblasts derived from the skin of control subjects and patients with varicose veins. The synthesis of collagen I, the release of its metabolites, and the expression of its mRNA were increased in fibroblasts from patients with varicose veins, whereas the synthesis of collagen III was decreased but not correlated with a decrease in mRNA expression and in metabolite release. Matrix metalloproteinases (MMP1, 2, 7, 8, 9, and 13) and their inhibitors (TIMP1 and 2) were quantified in both cell types; only the production of proMMP2 was increased in cells derived from patients with varicose veins.
CONCLUSIONS: These findings suggest that the synthesis of collagen I and III is dysregulated in dermal fibroblasts derived from patients with varicose veins. These results are comparable with those observed in smooth muscle cells derived from varicose veins, thus suggesting a systemic alteration of tissue remodeling in subjects with varicose veins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135949     DOI: 10.1161/01.cir.0000022846.22923.46

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Flow cytometric characterization of the saphenous veins endothelial cells in patients with chronic venous disease and in patients undergoing bypass surgery: an exploratory study.

Authors:  Cláudia Torres; Rui Machado; Margarida Lima
Journal:  Heart Vessels       Date:  2019-06-21       Impact factor: 2.037

2.  Venous pathophysiology.

Authors:  Chieh-Min Fan
Journal:  Semin Intervent Radiol       Date:  2005-09       Impact factor: 1.513

3.  Does extracellular matrix of the varicose vein wall change according to clinical stage?

Authors:  Mehmet Ali Demirkıran; Cüneyt Köksoy; Aylin Okçu Heper; Uğur Bengisun
Journal:  Ulus Cerrahi Derg       Date:  2014-12-01

Review 4.  Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.

Authors:  Arda Kucukguven; Raouf A Khalil
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

5.  The extracellular matrix is a novel attribute of endothelial progenitors and of hypoxic mature endothelial cells.

Authors:  Sravanti Kusuma; Stephen Zhao; Sharon Gerecht
Journal:  FASEB J       Date:  2012-08-23       Impact factor: 5.191

6.  From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases.

Authors:  Raffaele Serra; Luca Gallelli; Lucia Butrico; Gianluca Buffone; Francesco G Caliò; Giovanni De Caridi; Mafalda Massara; Andrea Barbetta; Bruno Amato; Miriam Labonia; Selena Mimmi; Enrico Iaccino; Stefano de Franciscis
Journal:  Int Wound J       Date:  2016-03-15       Impact factor: 3.315

7.  Expression and significance of NELIN and SM22α in varicose vein tissue.

Authors:  Shihui Chen; Shiyong Qin; Minghai Wang; Shuguang Zhang
Journal:  Exp Ther Med       Date:  2015-01-08       Impact factor: 2.447

8.  Tissue remodeling investigation in varicose veins.

Authors:  Sayyed Mohammad Hossein Ghaderian; Zohreh Khodaii
Journal:  Int J Mol Cell Med       Date:  2012

Review 9.  Latest Innovations in the Treatment of Venous Disease.

Authors:  Robert R Attaran
Journal:  J Clin Med       Date:  2018-04-11       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.